Breast Cancer Market

Market Overview:

The 7 major breast cancer markets are expected to exhibit a CAGR of 5.58% during 2024-2034.

The breast cancer market has been comprehensively analyzed in IMARC's new report titled "Breast Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Breast cancer is a type of oncological disease that develops when unhealthy cells in the breast grow and divide uncontrollably, forming a tumor. This tumor can invade surrounding tissues and potentially spread to other parts of the body through the lymphatic system or bloodstream. The ailment may not cause noticeable symptoms in the early stages; however, as cancer progresses, indications may include a lump or thickening in the breast or underarm, nipple discharge, skin ulceration, changes in breast size or shape, persistent pain, tenderness, etc. The diagnosis of this illness typically involves a combination of the patient's medical history, physical examination, and clinical findings. Various imaging studies, such as mammography, ultrasound, magnetic resonance imaging (MRI), etc., may be used to evaluate the affected region. These investigations help to visualize the breast tissue and can detect any abnormalities or suspicious areas. Furthermore, the healthcare provider may recommend a biopsy, along with its pathological analysis, to determine if cancerous cells are present and, if so, to classify the type of tumor.

The increasing cases of mutations in genes that are involved in repairing damaged DNA and maintaining the stability of the cell's genetic material are primarily driving the breast cancer market. In addition to this, the rising prevalence of various associated risk factors, such as hormonal imbalance, advancing age, early menstruation or late menopause, obesity, exposure to certain radiation, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of breast-conserving surgery, which provides substantial psychological and emotional benefits for women who are willing to maintain the natural appearance of their breasts, is further bolstering the market growth. Apart from this, the inflating application of immunotherapy, since it works by enhancing the body's defense system to recognize and attack cancerous cells while sparing healthy tissues, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of intensity-modulated radiation therapy, owing to its numerous advantages, like precise dose delivery, reduced side effects, and improved treatment flexibility, is expected to drive the breast cancer market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the breast cancer market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for breast cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the breast cancer market in any manner.

Recent Developments:

• In April 2024, AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) was approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have undergone prior systemic therapy for unresectable or metastatic disease.

Key Highlights:

• Breast cancer is one of the most often diagnosed malignancies and the fifth leading cause of cancer-related deaths, with an estimated total of 2.3 million new cases worldwide.
• Approximately half of all breast cancers arise in women who have no identifiable risk factors other than age and sex.
• Breast cancer affects approximately 99% of women, whereas men account for 0.5-1% of cases.
• Currently, over 80% of patients with breast cancer are over the age of 50.
• Black women die at the highest rate from breast cancer.

Drugs:

Arimidex is used to treat early breast cancer in postmenopausal women, either alone or in combination with other treatments, including surgery or radiation. It can also be used as the first-line treatment of advanced breast cancer that has spread within the breast or to other parts of the body.

SV-BR-1-GM is an immunization for breast cancer and other solid tumors developed by BriaCell Therapeutics. It is an allogeneic, whole-cell vaccination created from irradiated breast cancer cells that have been genetically engineered to produce granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF is an immunostimulant with potential antineoplastic and immunostimulatory effects.

LOXO-783 is an investigational (or experimental) medication that can be used orally to treat certain cancers. It is developed to target a specific abnormality (known as a PIK3CA mutation) that can occur in certain types of cancer cells and may be associated with disease progression.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the breast cancer market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the breast cancer market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current breast cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the breast cancer market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the breast cancer market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the breast cancer market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of breast cancer across the seven major markets?
• What is the number of prevalent cases (2018-2034) of breast cancer by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of breast cancer by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with breast cancer across the seven major markets?
• What is the size of the breast cancer patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of breast cancer?
• What will be the growth rate of patients across the seven major markets?
   

Breast Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for breast cancer drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the breast cancer market?
• What are the key regulatory events related to the breast cancer market?
• What is the structure of clinical trial landscape by status related to the breast cancer market?
• What is the structure of clinical trial landscape by phase related to the breast cancer market?
• What is the structure of clinical trial landscape by route of administration related to the breast cancer market?